Therapeutic targeting of β-catenin in cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Aberrant WNT/β-catenin signaling, driven by β-catenin mutations, is a major oncogenic pathway in ~10% of human cancers.
• This pathway is crucial for cancer initiation, progression, and maintenance.
• Directly targeting β-catenin has been a long-standing challenge in drug discovery.

Purpose of the Study:

• To review opportunities and challenges in developing therapies targeting β-catenin.
• To highlight recent progress in targeting this key oncogenic driver.
• To discuss the potential of β-catenin-targeted therapies for unmet patient needs.

Main Methods:

• Review of scientific literature on WNT/β-catenin pathway and β-catenin targeting strategies.
• Analysis of recent advancements in drug discovery approaches for β-catenin.
• Discussion of therapeutic implications for various cancer types.

Main Results:

• Significant progress has been made in understanding WNT/β-catenin signaling in cancer.
• Novel approaches are emerging to directly target β-catenin, overcoming previous limitations.
• Targeting β-catenin is transitioning from an "undruggable" target to a potential reality.

Conclusions:

• Directly targeting β-catenin offers a promising therapeutic strategy for cancers driven by WNT/β-catenin alterations.
• Effective therapies could address significant unmet needs in colorectal cancer, hepatocellular carcinoma, and other malignancies.
• Recent breakthroughs suggest the feasibility of developing drugs against this central oncogenic driver.